Compare Funko Inc (FNKO) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Heron Therapeutics Inc — how do they compare? Funko Inc trades at $6.44 (market cap $363.97M), while Heron Therapeutics Inc trades at $0.41 (market cap $68.01M). The key difference: Funko Inc is far larger — about 5.4× Heron Therapeutics Inc's market cap, and Funko Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Funko Inc for 33 Days and Heron Therapeutics Inc for 35 Days on average.
| FNKO | HRTX | |
|---|---|---|
Market Cap | $363.97M | $68.01M |
Volume | 1,422,651 | 1,891,941 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.10 | $1.49 |
52-Week Low | $2.81 | $0.27 |
Typical Hold Time | 33 Days | 35 Days |
Enterprise Value | $584.62M | $174.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Funko (FNKO) trades at $6.50, up 3.01% with strong technical momentum and bullish moving averages. The company shows improving fundamentals with recent earnings beats and raised EBITDA guidance, though profitability remains challenged with negative net margins. Analyst consensus leans Hold with a $7.58 price target, while institutional sentiment is mixed amid ongoing business transformation efforts.
Investment outlook balances technical strength against fundamental challenges. The stock offers potential upside to analyst targets but faces execution risks in maintaining recent operational improvements. Key catalysts include continued margin expansion and debt reduction, while risks include consumer discretionary spending pressures and competitive market positioning.
Heron Therapeutics (HRTX) trades at $0.36, down 8.15% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst sentiment remains overwhelmingly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX presents a high-risk opportunity with strong analyst support but fundamental challenges. The bullish technical setup and institutional confidence contrast with persistent losses and negative cash flow from operations. Investors face upside from potential operational improvements against the risk of continued financial underperformance in the competitive biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
